Skip to main content

Potent Immunotherapeutic Effects of Anti-PD-L1 in an Orthotopic Murine Bladder Tumor Model

Thursday, September 17, 2015 — Poster Session III

3:30 p.m. – 5:00 p.m.
FAES Terrace


  • AJ Vandeveer
  • JK Fallon
  • KW Hance
  • Y Lan
  • H Sabzevari
  • J Schlom
  • JW Greiner


In recent years, the emergence in the understanding that inhibitory immune receptors and their ligands play in the ability of tumors to evade an adaptive immune response has been a major advance in clinical immunotherapy. Previous studies illustrated that blocking antibodies for CTLA-4 or PD-1 resulted in clinical responses in many malignancies. PD-L1 has also emerged as a potential target. PD-L1 co-localizes with TILs that express IFNγ. It is hypothesized that PD-L1 induction represents tumor escape from T cell lysis. T cell checkpoint inhibitor efficacy is often increased against tumor types with high mutation rates and a high probability of generating an inherent T cell response. Much of the early attention has focused on Melanoma, NSCLC, and Bladder cancer. Antibodies that block PD-1/PD-L1 interactions have shown efficacy against these cancer types in early-stage clinical trials. In patients diagnosed with Bladder cancer, PD-L1 expression has been reported to correlate with high-grade tumors, a high recurrence rate, and reduced survival rate. The present study was designed to investigate the effects of an anti-PD-L1 antibody in an experimental murine bladder cancer model. Both murine and human (J82, T24, TCCSUP) bladder cancer cell lines express PD-L1 (flow cytometry), and in vitro IFN-γ addition upregulated PD-L1 expression levels on each of those tumor cells. A human IgG1 anti-PD-L1 antibody, Avelumab, was used to study the effects of targeting PD-L1 expression in MB49, murine bladder tumor cells. The model consists of either s.c. tumors or MB49-luc cells instilled intravesically into the bladders of syngeneic mice.

Category: Immunology